Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals declared that its board has authorized a stock repurchase program on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings results on Thursday, April, 27th. The company reported $1.38 EPS for the quarter, beating the Zacks' consensus estimate of $1.05 by $0.33. The business earned $870 million during the quarter, compared to analysts' expectations of $826.63 million. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. The company's revenue was up 24.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.11 EPS. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals updated its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $5.10-5.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.25. The company issued revenue guidance of $3.4-3.5 billion, compared to the consensus revenue estimate of $3.47 billion.

23 equities research analysts have issued 1 year price objectives for Alexion Pharmaceuticals' stock. Their predictions range from $120.00 to $221.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $162.14 in the next twelve months. View Analyst Ratings for Alexion Pharmaceuticals.

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

• 1. Morgan Stanley analysts commented, "re-prioritize the strategic direction" of the company. Furthermore, the second-quarter strategic review serves as a "turning point" for investor sentiment."While we understand investor unease that another 'shoe could drop' on this story, we see the risk/reward as compelling and believe new management is making progress right sizing the company and refocusing its efforts," the analyst wrote.2. Underappreciated StoryHarrison also believes Alexion's stock is pricing "little-to-no value" for the ALXN1210 life-cycle extension strategy. Meanwhile, investors are under-appreciating the antibody but the sentiment could turn move positive with potential gMG approval and the release of pivotal data.Harrison also believes Alexion's core asset value is "not impaired." Also, the analyst suggested that the underlying patient need and use of Solaris is "sound" and the company's strategy to protect Solaris through new IP and ALXN1210 is "very defensible with clarity on this strategy coming in less than 12 months." (5/25/2017)
• 2. J P Morgan Chase & Co analysts commented, "Anavex announced positive preclinical data for 2-73 in several neurodevelopmental disorders: Angelman, Fragile X and Rett syndromes." (5/23/2017)
• 3. Barclays PLC analysts commented, "provides support to the patient association in Brazil in the form of unrestricted educational grants and in accordance with local laws and regulations and industry code." In addition, the spokesperson confirmed that Alexion has not been charged with any criminal or civil misconduct.Investors Shrug Barclays' CallShortly after reports of Alexion's raid on Monday, analysts at Barclays offered a quick take on how investors should react.Barclays' Geoff Meacham suggested that while the headline report looks "onerous," the report shouldn't be viewed as a major fundamental concern. The analyst cited "good Soliris growth" (5/9/2017)
• 4. Cowen and Company analysts commented, "We recently hosted investor meetings with CEO Ludwig Hantson, CFO Dave." (4/28/2017)
• 5. According to Zacks Investment Research, "Alexion's guidance for 2017 was tepid signaling the slowdown of sales. Sales of Soliris have weakened in recent quarters thereby dampening growth prospects. Soliris’ revenue growth will also be impacted by the enrollment ramp-up of trials on ALXN1210 (by $70 million - $110 million). The drug is also witnessing access challenges in Latin America. Additionally, Alexion has faced significant setbacks in its attempts to expand Soliris’ label. Moreover, ongoing focus on drug pricing and sudden departure of its key executives in the middle of an internal probe into the sales practices related to Soliris are concerning. The probe revealed a material weakness in Alexion’s internal controls over financial reporting. Shares of Alexion have underperformed the broader industry in the past one year. Estimates have reduced lately ahead of the Q1 earnings results. Alexion has a positive record of earnings surprises in recent quarters." (4/18/2017)

Some companies that are related to Alexion Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Myovant Sciences Ltd (MYOV), Anika Therapeutics (ANIK), Syros Pharmaceuticals (SYRS), ChemoCentryx (CCXI), Sinovac Biotech (SVA), Syndax Pharmaceuticals (SNDX), Fortress Biotech (FBIO), Kamada (KMDA), Kadmon Holdings (KDMN), Mereo BioPharma Group PLC (MPH), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), Cardiome Pharma Corporation (CRME), VIVUS (VVUS), Strongbridge Biopharma PLC (SBBP) and Vericel Corporation (VCEL).

Alexion Pharmaceuticals' management team includes the folowing people:

• David R. Brennan, Chairman of the Board
• Ludwig N. Hantson Ph.D., Chief Executive Officer, Director
• David John Anderson, Chief Financial Officer
• Clare Carmichael, Chief Human Resource Officer, Executive Vice President
• John B. Moriarty J.D., Executive Vice President, General Counsel
• Martin Mackay Ph.D., Executive Vice President, Global Head - Research and Development
• Julie O'Neill, Executive Vice President - Global Operations
• Carsten Thiel Ph.D., Executive Vice President, Chief Commercial Officer
• Edward Miller J.D., Senior Vice President, Global Chief Compliance Officer
• Heidi L. Wagner J.D., Senior Vice President - Global Governmental Affairs

Alexion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (0.00%), BlackRock Inc. (0.00%), Vanguard Group Inc. (0.00%), State Street Corp (5.03%), Jennison Associates LLC (4.28%) and Ameriprise Financial Inc. (2.75%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Martin Mackay, Saqib Islam and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Alexion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Waddell & Reed Financial Inc., Alliancebernstein L.P., Parametric Portfolio Associates LLC, TCW Group Inc., Thrivent Financial For Lutherans, Sachem Head Capital Management LP and TIAA CREF Investment Management LLC. Company insiders that have sold Alexion Pharmaceuticals stock in the last year include Alvin S Parven, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell and Vikas Sinha. View Insider Buying and Selling for Alexion Pharmaceuticals.

Alexion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, State Street Corp, Marshall Wace North America L.P., Ameriprise Financial Inc., Vanguard Group Inc., Bank of New York Mellon Corp and Clearbridge Investments LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $125.81.